Dasatinib in imatinib-resistant or -intolerant CML patients: Data from the clinical practice of 6 hematological centers in the Czech Republic

Neoplasma

Volumn 57, Issue 4, 2010, Pages 355-359

  Klamova, H ^a   Faber, E ^b   Zackova, D ^c   Markova, M ^a   Voglova, J ^d   Cmunt, E ^e   Novakova, L ^f   Machova Polakova, K ^a   Moravcova, J ^a   Dvorakova, D ^c   Michalova, K ^a,e   Brezinova, J ^a   Oltova, A ^a   Jarosova, M ^c   Cetkovsky, P ^a   Indrak, K ^b   Mayer, J ^c  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Dasatinib; Mutation

Indexed keywords

DASATINIB; IMATINIB; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CYTOGENETICS; CYTOPENIA; CZECH REPUBLIC; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SALVAGE THERAPY; SURVIVAL RATE; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955295583     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_04_355     Document Type: Article

References (13)

1. HEHLMANN R, HOCHHAUS A, BACCARANI M. Chronic myeloid leukemia. Lancet 2007, 370: 342-50. doi:10.1016/ S0140-6736(07)61165-9
2. DRUCKER BJ, GUILHOT F, O'BRIEN SG, GATHMANN I, KANTARJIAN H. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355: 2408-2417 doi:10.1056/NEJMoa062867
3. MELO JV, CHUAH CH. Novel agents on CML therapy: Tyrosine kinase inhibitors and Beyond. Hematology Am Soc Hematol Educ Program. 2008: 427-435
4. HOCHHAUS A., KANTARJIAN HM, BACCARANI M, LIPTON JH, APPERLEY JF. Dasatinib induced notable hematological and cytogenetic response in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109:2303-2309 doi:10.1182/blood-2006-09-047266
5. CORTES J, ROUSSELOT P, KIM DW, RITCHIE E, HAMERSCHLAK N. Dasatinib induces complete hematological and cytogenetic response in patiens with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood 2007,109, 3207-3213. doi:10.1182/blood-2006-09-046888
6. MUELLER MC, ERBEN P, ERNST T, GIEHL M, SCHENK T. Molecular response according to type of preexisting BCR-ABL mutations after second-line dasatinib therapy in population. Blood 2007,110, 100a-101a
7. MAYER J, KLAMOVA H, ZACKOVA D, DOUBEK M, CETKOVSKY P. Imatinib in the first-line CML treatment: an analysis of comprehensive non-commercial database of all consecutive patients in a defined population. Haematologica; 2008; 93:S1, 224 (Abs.554)
8. FABER E, MUZIK J, KOZA V, DEMECKOVA E, VOGLOVA J. Comparision of allogeneic stem cell transplantation and imatinib for chronic myeloid leukemia: results from Camelia registry. Haematologica 2008; 93: S1, 224 (Abs.553)
9. BACCARANI M, SAGLIO G, GOLDMAN J, HOCHHAUS A, SIMONSSON B. Evolving concepts in the management of chronic myeloid leukemia: recommendation from an expert panel in behalf of the European LeukemiaNet. Blood 2006, 108: 1809-1820. doi:10.1182/blood-2006-02-005686
10. BRANFORD S, HUGHES T. Detection of BCR-ABL mutation and resistance to imatinib mesylate. In: Iland H, Hertzberg M, Marlton P, eds. Myeloid Leukemia: Methods and Protocols, Totowa, NJ: Humana Press Inc, 2005: 93-106. doi:10.1385/1-59745-017-0:93
11. SHAH NP, KANTARJIAN HM, KIM DW, DORLHIACLLACER PE, MILONE JH. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and intolerant CP-CML. Journal of Clinical Oncology 2008, 26: 3204-3212 doi:10.1200/JCO.2007.14.9260
12. CANG S, LIU D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. Journal of Hematology & Oncology 2008, 1: 15
13. HOCHHAUS A, BACCARANI M, DEININGEN M, APPERLEY JF, LIPTON JH. Dasatinib induces durable cytogenetic response in patiens with chronic myelogenous leukemia in chronic phase with resistence or intolerance to imatinib. Leukemia 2008, 22: 1200-1206 doi:10.1038/ leu.2008.84